@article{d46160939f7d43eea7e5efab157f41a7,
title = "Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference",
abstract = "Chronic kidney disease (CKD) is a major risk factor for valvular heart disease (VHD). Mitral annular and aortic valve calcifications are highly prevalent in CKD patients and commonly lead to valvular stenosis and regurgitation, as well as complications including conduction system abnormalities and endocarditis. VHD, especially mitral regurgitation and aortic stenosis, is associated with significantly reduced survival among CKD patients. Knowledge related to VHD in the general population is not always applicable to CKD patients because the pathophysiology may be different, and CKD patients have a high prevalence of comorbid conditions and elevated risk for periprocedural complications and mortality. This Kidney Disease: Improving Global Outcomes (KDIGO) review of CKD and VHD seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of VHD in CKD by summarizing knowledge gaps, areas of controversy, and priorities for research.",
author = "Marwick, {Thomas H.} and Kerstin Amann and Sripal Bangalore and Cavalcante, {Jo{\~a}o L.} and Charytan, {David M.} and Craig, {Jonathan C.} and Gill, {John S.} and Hlatky, {Mark A.} and Jardine, {Alan G.} and Ulf Landmesser and Newby, {L. Kristin} and Herzog, {Charles A.} and Michael Cheung and Wheeler, {David C.} and Winkelmayer, {Wolfgang C.} and Sarnak, {Mark J.} and Debasish Banerjee and Carlo Briguori and Chang, {Tara I.} and Chen, {Chien Liang} and deFilippi, {Christopher R.} and Xiaoqiang Ding and Ferro, {Charles J.} and Jagbir Gill and Mario G{\"o}ssl and Isbel, {Nicole M.} and Hideki Ishii and Jardine, {Meg J.} and Kalra, {Philip A.} and G{\"u}nther Laufer and Lentine, {Krista L.} and Lobdell, {Kevin W.} and Lok, {Charmaine E.} and London, {G{\'e}rard M.} and Jolanta Ma{\l}yszko and Mark, {Patrick B.} and Mohamed Marwan and Yuxin Nie and Parfrey, {Patrick S.} and Roberto Pecoits-Filho and Helen Pilmore and Qunibi, {Wajeh Y.} and Paolo Raggi and Marcello Rattazzi and Patrick Rossignol and Josiah Ruturi and Charumathi Sabanayagam and Shanahan, {Catherine M.} and Shroff, {Gautam R.} and Rukshana Shroff and Webster, {Angela C.} and Weiner, {Daniel E.} and Simon Winther and Wiseman, {Alexander C.} and Anthony Yip and Alexander Zarbock",
note = "Funding Information: The conference was sponsored by Kidney Disease: Improving Global Outcomes (KDIGO) and supported in part by unrestricted educational grants from Akebia Therapeutics, Amgen, Boehringer Ingelheim, Corvidia, Daiichi-Sankyo, Fresenius Medical Care, Kyowa Kirin, and Suntop Healthcare Corp. We thank Jennifer King for assistance with manuscript preparation. Funding Information: JLC declared having received consultancy fees from HighLife Medical and Medtronic; speaker honoraria from Siemens; and research support from Boston Scientific, Edwards Lifesciences, Medtronic, and Siemens. DMC declared having received consultancy fees from Allena, Amgen, AstraZeneca, Daiichi-Sankyo, Fresenius, Gilead, Janssen, Medtronic/Covidien, Merck, Novo Nordisk, and Zoll Medical; speaker honoraria from Fresenius; research support from Amgen, Gilead, Medtronic, National Institutes of Health (NIH), and Novo Nordisk; and serving as an expert witness. MAH is expected to receive fees for future consultancy work from Tricida. UL declared having received consultancy fees from Amgen, Bayer, Medicines Company, and Sanofi. CAH declared having received consultancy fees from AbbVie, American College of Cardiology/American Diabetes Association, Amgen, AstraZeneca, Corvidia, DiaMedica, FibroGen, Janssen, Oxford University, OxThera, Pfizer, and Relypsa; stock equity from Boston Scientific, General Electric, Johnson & Johnson, and Merck; and research support from Amgen, Bristol-Myers Squibb, National Institute of Diabetes and Digestive and Kidney Diseases, NIH/National Heart, Lung, and Blood Institute, Relypsa, and the University of British Columbia. DCW declared having received consultancy fees from Amgen, AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Napp/Mundipharma, Mitsubishi Tanabe, and Vifor Fresenius; and speaker honoraria from Amgen and Napp/Mundipharma. WCW declared having received consultancy fees from Akebia, AMAG, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and ZS Pharma; honoraria from FibroGen; and research support from the NIH. MJS declared having received consultancy fees from Bayer and research support from Akebia. All the other authors declared no competing interests. Publisher Copyright: {\textcopyright} 2019 The Authors",
year = "2019",
month = oct,
doi = "10.1016/j.kint.2019.06.025",
language = "English",
volume = "96",
pages = "836--849",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",
}